144 related articles for article (PubMed ID: 30986169)
1. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma.
Sutaria R; Patel P; Danve A
Eur J Rheumatol; 2019 Jul; 6(3):153-154. PubMed ID: 30986169
[TBL] [Abstract][Full Text] [Related]
2. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
Fazel M; Jedlowski PM
Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
Werner JM; Schweinsberg V; Schroeter M; von Reutern B; Malter MP; Schlaak M; Fink GR; Mauch C; Galldiks N
Front Oncol; 2019; 9():84. PubMed ID: 30828569
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
[TBL] [Abstract][Full Text] [Related]
8. Myasthenia Gravis-Like Syndrome Resulting From Immune Checkpoint Inhibitors in a Patient With Urothelial Carcinoma.
Vivas AJ; Chaudhry U; Punchayil Narayanankutty N; Lopez R; Lamarche J
Cureus; 2024 May; 16(5):e60003. PubMed ID: 38854361
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia Gravis Induced by Nivolumab: A Case Report.
Mehta JJ; Maloney E; Srinivasan S; Seitz P; Cannon M
Cureus; 2017 Sep; 9(9):e1702. PubMed ID: 29159009
[TBL] [Abstract][Full Text] [Related]
11. A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.
Utsunomiya A; Oyama N; Iino S; Baba N; Chino T; Utsunomiya N; Hasegawa M
Case Rep Dermatol; 2018; 10(1):1-6. PubMed ID: 29515387
[TBL] [Abstract][Full Text] [Related]
12. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
13. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.
Montes V; Sousa S; Pita F; Guerreiro R; Carmona C
Front Neurol; 2018; 9():150. PubMed ID: 29666602
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
16. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
17. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
19. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
